These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 22539090)

  • 1. Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent.
    Shin SJ; Hwang JW; Ahn JB; Rha SY; Roh JK; Chung HC
    Invest New Drugs; 2013 Feb; 31(1):1-13. PubMed ID: 22539090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops.
    Adamcic U; Skowronski K; Peters C; Morrison J; Coomber BL
    Neoplasia; 2012 Jul; 14(7):612-23. PubMed ID: 22904678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
    Ding C; Li L; Yang T; Fan X; Wu G
    BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2.
    Zhang Z; Neiva KG; Lingen MW; Ellis LM; Nör JE
    Cell Death Differ; 2010 Mar; 17(3):499-512. PubMed ID: 19834490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Endothelial SCUBE2 (Signal Peptide-CUB-EGF Domain-Containing Protein 2), a Novel VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) Coreceptor, Suppresses Tumor Angiogenesis.
    Lin YC; Liu CY; Kannagi R; Yang RB
    Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1202-1215. PubMed ID: 29545238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling.
    Chen H; Cong Q; Du Z; Liao W; Zhang L; Yao Y; Ding K
    Cancer Lett; 2016 Nov; 382(1):44-52. PubMed ID: 27569654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
    Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
    Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selenadiazole Derivatives Inhibit Angiogenesis-Mediated Human Breast Tumor Growth by Suppressing the VEGFR2-Mediated ERK and AKT Signaling Pathways.
    Lai H; Fu X; Sang C; Hou L; Feng P; Li X; Chen T
    Chem Asian J; 2018 Jun; 13(11):1447-1457. PubMed ID: 29575811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. α-santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT/mTOR/P70S6K signaling pathway.
    Saraswati S; Kumar S; Alhaider AA
    Mol Cancer; 2013 Nov; 12():147. PubMed ID: 24261856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPemd26, an anthraquinone derivative, suppresses angiogenesis via inhibiting VEGFR2 signalling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Br J Pharmacol; 2014 Dec; 171(24):5728-42. PubMed ID: 25091695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells.
    Doi Y; Yashiro M; Yamada N; Amano R; Noda S; Hirakawa K
    Ann Surg Oncol; 2012 Aug; 19(8):2733-43. PubMed ID: 22207048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers for antitumor activity of bevacizumab in gastric cancer models.
    Yamashita-Kashima Y; Fujimoto-Ouchi K; Yorozu K; Kurasawa M; Yanagisawa M; Yasuno H; Mori K
    BMC Cancer; 2012 Jan; 12():37. PubMed ID: 22273502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Norcantharidin inhibits tumor angiogenesis via blocking VEGFR2/MEK/ERK signaling pathways.
    Zhang L; Ji Q; Liu X; Chen X; Chen Z; Qiu Y; Sun J; Cai J; Zhu H; Li Q
    Cancer Sci; 2013 May; 104(5):604-10. PubMed ID: 23363445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.
    Terme M; Pernot S; Marcheteau E; Sandoval F; Benhamouda N; Colussi O; Dubreuil O; Carpentier AF; Tartour E; Taieb J
    Cancer Res; 2013 Jan; 73(2):539-49. PubMed ID: 23108136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis.
    Bi YL; Mi PY; Zhao SJ; Pan HM; Li HJ; Liu F; Shao LR; Zhang HF; Zhang P; Jiang SL
    Int J Mol Med; 2017 May; 39(5):1255-1261. PubMed ID: 28358414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antihypertension drug doxazosin inhibits tumor growth and angiogenesis by decreasing VEGFR-2/Akt/mTOR signaling and VEGF and HIF-1α expression.
    Park MS; Kim BR; Dong SM; Lee SH; Kim DY; Rho SB
    Oncotarget; 2014 Jul; 5(13):4935-44. PubMed ID: 24952732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Particled Mica, STB-HO has chemopreventive potential via G1 arrest, and inhibition of proliferation and vascular endothelial growth factor receptor 2 in HCT colorectal cancer cells.
    Cho SY; Lee HJ; Cho SM; Kim B; Jung YK; Kim SH
    BMC Complement Altern Med; 2013 Jul; 13():189. PubMed ID: 23883349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
    Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
    Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
    Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
    Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.